Interleukin-6 gene polymorphisms and susceptibility to liver diseases
A meta-analysis

Xuehan Wang, PhD∗,*a, Zhenghui Yan, MSa, Qingjian Ye, MMD,∗

Abstract
Background: Several studies have explored the associations between interleukin-6 (IL-6) gene polymorphisms and the susceptibility to liver diseases, however, results remain ambiguous. The goal of this study was to conduct a meta-analysis to provide more credible evidence.

Methods: Studies identified in the PubMed, Cochrane Library, and EMBASE databases were used to perform a meta-analysis via the STATA software. Pooled odds ratios (OR) were calculated under fixed- and random-effects models to estimate the potential genetic associations.

Results: Twenty-five case-control studies involving 5813 cases and 5298 controls were included in this meta-analysis. Overall, the pooled results suggested that rs1800795 polymorphism was significantly associated with the risk of liver diseases in heterozygote (GC vs CC; OR = 1.57) and dominant (GG+GC vs CC: OR = 1.47) models; rs1800796 polymorphism was significantly associated with the susceptibility to liver diseases in heterozygote (GG vs GC; OR = 0.59) and recessive (GG vs GC+CC: OR = 0.68) models; rs1800797 polymorphism was significantly associated with genetic predisposition to liver diseases in homozygote (GG vs AA; OR = 1.63), heterozygote (GA vs AA; OR = 1.53) and dominant (GG + GA vs AA: OR = 1.61) models. A similar conclusion was found in the HBV, HCV, HCC, NASH and alcoholic liver disease of all ethnic populations for rs1800795; HBV and Asian subgroups for rs1800796; HCV and non-Asian subgroups for rs1800797. However, IL-6 rs2069837 and rs2066992 polymorphisms did not exhibit significant associations with the risk of liver diseases under any genetic models.

Conclusion: This meta-analysis suggests that patients carrying G (rs1800795), C (rs1800796) or G (rs1800797) allele or genotypes of IL-6 may be more likely to suffer from liver diseases, which was ethnic-dependent.

Abbreviations: CI = confidence interval, HBV = hepatitis B virus, HC = healthy, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, HIV = human immunodeficiency virus-type 1, IF = infection resolved, IL-6 = interleukin-6, LC = liver cirrhosis, NASH = nonalcoholic steatohepatitis, NOS = New-castle–Ottawa Scale, OR = odds ratio, PRISMA = Preferred Reporting Items for Systematic Review and Meta-analysis, SNP = single nucleotide polymorphism, STAT3 = signal transducer and activator of transcription 3.

Keywords: genetic variation, hepatitis B virus, hepatitis C virus, interleukin-6, liver diseases, transformation

1. Introduction

The liver is one of the key organs of the body, which performs many pivotal functions essential for human life, including carbohydrate, protein and fat metabolism,[1] immune response against pathogens[2] as well as detoxification of xenobiotic.[3] The consequence of hepatic impairments, including viral hepatitis, alcoholic or nonalcoholic steatohepatitis (NASH), drug-induced liver injury, autoimmune hepatitis, fatty liver, liver cirrhosis (LC) and liver cancer, may be serious and even lethal.[4] Thus, it is vital to understand the etiology of liver diseases for developing efficiently predictive, preventive and therapeutic strategies.

Despite the pathogenesis remains unclear, increasing evidence has suggested liver diseases are of an inflammatory nature.[5] Interleukin-6 (IL-6) is an important inflammatory cytokine and may play a central role for the development and progression of liver diseases. Serum IL-6 concentration was detected to be significantly higher in alcoholic or non-alcoholic cirrhosis and toxic hepatitis when compared to controls.[6] Higher level of IL-6 was observed to be produced in CD4(+) T cells from acute-on-
chronic hepatitis B virus (HBV) liver failure patients.\textsuperscript{7} Higher level of IL-6 was significantly associated with advanced liver fibrosis in human immunodeficiency virus-type 1 (HIV)-infected patients [adjusted odds ratio (OR) = 11.78, 95\% confidence interval (CI): 1.17–118.19, P = .036].\textsuperscript{8} High plasma IL-6 was also suggested as a biomarker for poor prognosis of patients with hepatocellular carcinoma (HCC).\textsuperscript{9} IL-6 promoted HCC cell proliferation and migration by activating signal transducer and activator of transcription 3 (STAT3) signaling pathway.\textsuperscript{9} These findings imply any factor that influences the expression of IL-6 may be an underlying contributor for the development of liver diseases.

Recently, some scholars have found genetic mutations in the IL-6 gene could alter its expression, with genotype CC carriers of rs1800796 showing higher level of IL-6 mRNA compared with genotype CG/GG carriers.\textsuperscript{11,12} Therefore, this IL-6 single nucleotide polymorphism (SNP) may be a possible risk factor to contribute to the susceptibility to liver diseases. This hypothesis has been validated as follows: genotyping of IL-6 rs1800796 SNP showed a significant increase in GC genotypes, but reduction in GG genotype in HBV infection group compared with controls. A direct positive correlation was also detected between HBV and the presence of GC genotype and C allele.\textsuperscript{13} Riazalhosseini et al also observed the frequency of allele G of rs1800796 was higher among healthy controls than that among chronic HBV patients (0.303 vs 0.258) and GC+CC genotype was associated with a protection mechanism against HBV infection (OR = 0.40, 95\% CI: 0.34–0.48).\textsuperscript{14} However, inconsistent conclusions were also reported, with no significant associations of rs1800796 polymorphism with HBV infection.\textsuperscript{13} hepatitis C virus (HCV) infection,\textsuperscript{16} LC and HCC.\textsuperscript{15,17} Furthermore, there were also studies to investigate the associations between the risk of liver diseases and other polymorphisms in IL-6, including rs1800795, rs1800797,\textsuperscript{13,16} rs2066992,\textsuperscript{18,19} and rs2069837\textsuperscript{14,18,20} and the controversial outcomes were also present in them. These equivocal results may be attributed to small sample size and limited statistical power of each individual study.

The goal of this study was to conduct a meta-analysis to comprehensively estimate the associations of IL-6 polymorphisms and genetic predisposition to all liver diseases.

2. Materials and methods

2.1. Literature search

Our study was performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) standard.\textsuperscript{21} PubMed, the Cochrane Library and EMBASE databases were searched for papers published before February, 2019 using the keywords: interleukin-6 (OR IL-6) AND polymorphism (OR SNP OR variant OR mutation) AND liver diseases (OR hepatitis OR liver cirrhosis OR hepatocellular carcinoma OR liver injury OR fatty liver). The publication language was restricted to English. Furthermore, potentially eligible literatures were supplemented through manually mining bibliographies of relevant studies.

2.2. Inclusion and exclusion criteria

Studies were included if they satisfied the following criteria:

1. human genotyping;
2. case-control design;
3. healthy (HC) or infection resolved (IF) controls;
4. evaluation of the associations between IL-6 polymorphisms and liver diseases in more than 2 articles; and
5. providing adequate data to calculate the OR and its corresponding 95\% CI.

Studies having the following characteristics were excluded:

1. repeated studies;
2. animal studies, reviews, case reports, series, meeting abstracts, as well as comment;
3. the data of genotype frequency were unavailable;
4. studies that investigated the therapy response; and
5. some controls showing HBV positive or having other liver diseases.

2.3. Data extraction and quality assessment

Two investigators independently extracted the data from each eligible study, including first author’s name, year of publication, country, ethnicity, liver disease type, genotyping method, number of cases and controls, source of control, and frequency of genotypes. If articles included more than 1 disease type, each group was considered as an independent dataset. The quality of individual studies was also assessed independently by two authors using the New-castle–Ottawa Scale (NOS) system\textsuperscript{22} that includes 3 aspects: selection (0–4 points), comparability (0–2 points) and exposure (0–3 points). The NOS ranges from zero (worst) to 9 stars (best). Studies scored more than 7 stars were considered to be of high quality. Any disagreements in data extraction and quality assessment were resolved by the involvement of a third part.

2.4. Statistical analysis

STATA software (version 13.0; STATA Corporation, USA) was used for this meta-analysis. The associations between IL-6 polymorphisms (rs1800795, rs1800796, rs1800797, rs2066992, and rs2069837) and the risk of liver diseases were estimated based on pooled ORs and 95\% CI under various genetic models. P value of Cochran’s Q-statistic >0.1 or I\(^2\) value <50\% indicated the absence of heterogeneity among studies and thus of a fixed-effect model was utilized in the association test; otherwise (P < .10 or I\(^2\) > 50\%), a random-effect model was chosen. The significance of the pooled ORs was determined by the Z test, and P < .05 was considered statistically significant. Potential publication bias was evaluated using the Egger linear regression test. If there was evidence of publication bias (P < .05), trim and fill method was used to adjust for the effect of publication bias.\textsuperscript{23} Sensitivity analysis was performed to evaluate the stability of the results by omitting each study at a time.

3. Results

3.1. Study characteristics

The search strategy retrieved 1035 relevant papers. Based on the inclusion and exclusion criteria (Fig. 1), 25 case-control studies including 5813 cases and 5298 controls were finally included for this meta-analysis.\textsuperscript{12–16,18–20,24–40} Among these 25 studies published between 2005 and 2018, 17 of them with 20 datasets investigated the associations between rs1800795 polymorphism of IL-6 gene and liver diseases (including 1 for autoimmune
hepatitis, 3 for HBV infection, 4 for NASH, 4 for HCV infection, 3 for LC, 1 for HEV infection, 2 for HCC and 2 for alcoholic liver disease). 8 studies with 16 datasets involved rs1800796 (including 6 for HBV infection, 2 for HCV infection, 1 for HIV infection, 3 for LC, 3 for HCC and 1 for LC/HCC), 5 studies with 8 datasets analyzed rs1800797 (including 3 for HBV infection, 1 for HCV infection, 2 for LC and 2 for HCC), 4 studies with 5 datasets explored rs2069837 (including 2 for HBV infection, 1 for anti-tuberculosis drug-induced hepatitis, 1 for LC-HCC and 1 for HCC) and 3 studies with 4 datasets surveyed rs2066992 (including 2 for HBV infection, 1 for anti-tuberculosis drug-induced hepatitis and 1 for LC-HCC). According to the NOS, all the included studies were of high quality. The detailed characteristics of included studies are listed in Table 1.

3.2. Meta-analysis

The meta-analysis results of the correlations between five IL-6 polymorphisms and vulnerability to liver diseases in all genetic models are shown in Table 2. The pooled results suggested that rs1800795 polymorphism was significantly associated with the risk of liver diseases in heterozygote (GC vs CC: OR = 1.57, 95%
### Table 1: Characteristics of studies included in this meta-analysis.

| First author | Year | Country/ethnicity | Liver disease | Genotyping method | SNP | Source of control | Cases | Controls | NOS |
|--------------|------|------------------|---------------|-------------------|-----|-------------------|-------|----------|-----|
| Yourell A    | 2018 | Iran/Asian       | Autoimmune hepatitis | PCR-SSP | rs1800795 | PB  | HC | 57 | 140 | 9   |
| El-Maadawy EA | 2019 | Egypt/Non-Asian  | HBV           | MS-PCR            | rs1800795; rs1800796; | PB  | HC | 108 | 102 | 7   |
| Rizzalhosseni B | 2018 | Malaysia/Asian   | HBV           | MassARRAY         | rs1800796; | PB  | HC + IF | 423 | 623 | 7   |
| Kurbatova M  | 2017 | Russia/Non-Asian | HBV           | LC-HCC            | rs1800797; | PB  | HC | 103 | 97  |     |
| Becanc IC    | 2017 | Russia/Non-Asian | HBV           | PCR-PPRF          | rs1800795 | HB  | HC | 126 | 116 | 8   |
| Motazi T     | 2017 | Iran/Non-Asian   | HBV           | PCR-SSP           | rs1800795 | HB  | HC | 85  | 100 | 7   |
| Altar M      | 2016 | Iran/Asian       | HBV-hepatitis | PCR-SSP           | rs1800795 | HB  | HC | 65  |     |     |
| Zheng G      | 2015 | China/Asian      | HBV           | Taq PCR           | rs1800795 | PB  | HC | 297 | 368 | 7   |
| Wang J       | 2015 | China/Asian      | Anti-tuberculosis drug-induced hepatitis | PCR-RFLP, TaqMan | rs20669837, rs20669837, rs1524107 | PB  | HC | 566 | 618 | 8   |
| Lu Y         | 2014 | China/Asian      | HBV           | DNA sequencing    | rs1800796; rs1800797 | HB  | IF | 219 | 212 | 9   |
| Saeena R     | 2014 | India/Asian      | HBV           | PCR-RFLP          | rs1800796; rs1800797 | HB  | HC | 63  | 153 | 7   |
| Tarquap AM   | 2014 | Brazil/Non-Asian | HBV           | PCR-RFLP          | rs1800795 | PB  | HC | 69  | 47  | 8   |
| Deni S       | 2014 | India/Asian      | HBV           | PCR-RFLP          | rs1800795 | PB  | HC | 222 | 376 | 9   |
| Cengiz M     | 2014 | Turkey/Non-Asian | NASH          | PCR-RFLP          | rs1800795 | PB  | HC | 38  |     |     |
| Zhao XM      | 2013 | China/Asian      | HBV           | SNaPshot reaction | rs20669837, rs20669652 | HB  | IF | 501 | 301 | 9   |
| Tang S       | 2013 | China/Asian      | HBV, LC, HCC  | Taq PCR           | rs1800796 | PB  | HC | 330 | 265 | 8   |
| Gianthrapani L | 2011 | Italy/Asian      | LC, HCC       | PCR-RFLP          | rs1800795 | HB  | HC | 95  | 98  | 9   |
| Cussigh A    | 2011 | Italy/Asian      | HCV           | PCR-RFLP          | rs1800797; rs1800796; rs1800795 | PB  | HC | 424 | 344 | 7   |
| Fadili E     | 2009 | Italy/Asian      | LC, HCC       | PCR-RFLP          | rs1800797; rs1800795 | PB  | HC | 153 | 236 | 7   |
| Carulli L    | 2009 | Italy/Asian      | NASH          | PCR-RFLP          | rs1800795 | PB  | HC | 114 | 79  | 7   |
| Marcos M     | 2009 | Spain/Non-Asian  | NASH          | PCR-RFLP          | rs1800795 | PB  | HC | 95  | 259 | 7   |
| Greissen D   | 2008 | United Kingdom/Non-Asian | PCR-SSP | rs1800795 | PB  | HC | 223 | 79  | 7   |
| Ribeiro, CSS | 2007 | Brasil/Non-Asian | HBV           | TaqPCR            | rs206969837 and rs20669922 | PB  | IF | 30  | 41  |     |
| Minton EJ    | 2005 | United Kingdom/Non-Asian | HCV | TaqMan | rs1800795 | PB  | HC | 253 | 44  | 7   |

**ALD** = alcoholic liver disease, **HB** = hospital-based, **HBV** = hepatitis B virus, **HC** = healthy control, **HCC** = hepatocellular carcinoma, **HCV** = hepatitis C virus, **HEV** = hepatitis E virus, **HIV** = human immunodeficiency virus-type 1, **IF** = infection resolved, **LC** = liver cirrhosis, **MS** = mutagenically separated, **NASH** = non-alcoholic steatohepatitis, **NOS** = New-castle-Ottawa Scale, **PB** = population-based, **PCR-RFLP** = polymerase chain reaction restriction fragment length polymorphism, **SSP** = sequence-specific amplification.

CI = 1.32–1.88, P < .0001 (Fig. 2A) and dominant (GG + GC vs CC: OR = 1.47, 95% CI = 1.14–1.91, P < .0001) (Fig. 2B) models; rs1800796 polymorphism was significantly associated with the susceptibility to liver diseases in heterozygote (GG vs GC: OR = 0.58, 95% CI = 0.39–0.85, P = .006) (Fig. 3A) and recessive (GG vs GC + CC: OR = 0.68, 95% CI = 0.50–0.91, P = .009) (Fig. 3B) models; rs1800797 polymorphism was significantly associated with genetic predisposition to liver diseases in homozygote (GG vs AA: OR = 1.65, 95% CI = 1.17–2.27, P = .004) (Fig. 4A), heterozygote (GG vs AA: OR = 1.53, 95% CI = 1.09–2.14, P = .013) (Fig. 4B) and dominant (GG + GA vs AA: OR = 1.61, 95% CI = 1.17–2.22, P = .003) (Fig. 4C) models. However, IL-6 rs2069837 and rs20669922 polymorphisms did not exhibit significant associations with liver disease risk in any genetic model.

Due to the presence of significant heterogeneity in some overall analysis (Table 2), subgroup analyses were conducted based on liver disease type and ethnicity. For rs1800795 polymorphism, only a significant association was observed for patients with HBV [G vs C: OR = 1.75, 95% CI = 1.13–2.72, P = .012; GG vs CC: OR = 2.98, 95% CI = 1.63–5.45, P < .001; GC vs CC: OR = 2.08, 95% CI = 1.15–3.77, P = .016; GG+GC vs CC: OR = 2.54, 95% CI = 1.37–4.71, P = .003; GG vs GC+CC: OR = 1.91, 95% CI = 1.03–3.56, P = .041], NASH (GC vs CC: OR = 1.60, 95% CI = 1.03–2.49, P = .038), HCV (GC vs CC: OR = 1.58, 95% CI = 1.04–2.42, P = .034), HCC (GC vs CC: OR = 3.11, 95% CI = 1.24–7.79, P = .015) and alcoholic liver disease (GC vs CC: OR = 1.51, 95% CI = 1.03–2.21, P = .036; GC vs GG+CC: OR = 1.47, 95% CI = 1.03–2.10, P = .036) (Table 3). For rs1800796 polymorphism, only a significant association was detected for patients with HBV [G vs C: OR = 0.74, 95% CI = 0.65–0.85, P < .001; GC vs CC: OR = 0.56, 95% CI = 0.42–0.74, P < .001; GG vs GC: OR = 0.42, 95% CI = 0.20–0.87, P = .020; GG vs GC + CC: OR = 0.46, 95% CI = 0.29–0.73, P = .001] (Table 4). For rs1800797 polymorphism, no significant association was detected for most of liver disease patients other than HCV (Table 5), but only 1 literature was included for HCV and this result remained inconclusive. In both of Asian and non-Asian
population, a significant increased risk to develop liver diseases can be observed in G allelic carriers of rs1800795 polymorphism; G allele (OR = 0.87, 95% CI = 0.77–0.99, P = 0.037) or GG genotype (GG vs CC: OR = 0.77, 95% CI = 0.59–1.00, P = 0.046; GG vs GC: OR = 0.51, 95% CI = 0.30–0.85, P = 0.009; GG vs GC +CC: OR = 0.62, 95% CI = 0.43–0.85, P = 0.003) of rs1800796 polymorphism was related with the lower risk of liver diseases only in Asian population, but contrast results for the non-Asian (GC vs CC: OR = 1.76, 95% CI = 1.11–2.79, P = 0.017; GG vs GC +CC: OR = 1.85, 95% CI = 1.20–2.88, P = 0.006); rs1800797 polymorphism was significantly associated with the susceptibility to liver diseases only in non-Asian population (GG vs AA: OR = 1.75, 95% CI = 1.12–2.53, P = 0.03; GG vs AA: OR = 1.72, 95% CI = 1.19–2.49, P = 0.04; GG+GA vs AA: OR = 1.76, 95% CI = 1.24–2.51, P = 0.002) (Table 6).

3.3. Publication bias and sensitivity analysis

Egger linear regression test was performed to investigate the potential publication bias for significant results in overall meta-analysis. The results showed the intercept did not pass through the origin (that is, asymmetry) in association analysis of rs1800796 under heterozygote model (GG vs GC) (Fig. 5A), indicating the presence of publication bias (P = 0.017). Subsequently, trim and fill method was used to further adjust for the publication bias (Fig. 5B). The results showed the association remained significant after correcting the publication bias (OR = 0.76, 95% CI = 0.64–0.90, P = 0.001), implying our results were statistically robust. No obvious asymmetry was observed in the evaluation of publication bias for rs1800795 (GC vs CC: P = 0.072; GG+GC vs CC: P = 0.182) and rs1800797 (GG vs AA: P = 0.242; GA vs AA: OR = 1.53, P = 0.316; GG + GA vs AA: P = 0.321), suggesting no evidence of publication bias.

As shown in Figure 6, the omission of any single study did not significantly affect the pooled ORs or 95% CIs, indicating our results may be reliable.

4. Discussion

In this study, we performed a meta-analysis to investigate the associations of IL-6 SNPs with liver diseases. Our findings showed that IL-6 rs1800795 and rs1800796 polymorphisms may be potential genetic factors for the development of liver diseases. Patients with G allele or GG, GC and GG+GC genotypes of
Figure 2. Forest plots of the association of IL-6 gene rs1800795 polymorphism with an increased risk of liver diseases under heterozygote (GC vs CC) and dominant (GG+GC vs CC) models. A, heterozygote; B, dominant. CI = confidence intervals; OR = odds ratio.
Figure 3. Forest plots of the association of IL-6 gene rs1800796 polymorphism with an increased risk of liver diseases under heterozygote (GC vs CC) and recessive (GG vs GC+CC) models. A, heterozygote; B, recessive. CI = confidence intervals; OR = odds ratio.

| Study ID          | OR (95% CI) | Weight |
|-------------------|-------------|--------|
| Study ID          | OR (95% CI) | Weight |
| Falletti E (2009) | 1.20 (0.69, 2.08) | 7.16 |
| Falletti E (2009) | 0.80 (0.34, 1.89) | 5.91 |
| Cussigh A (2011)  | 1.14 (0.84, 1.54) | 7.95 |
| Tang S (2013)     | 0.90 (0.37, 2.18) | 5.81 |
| Tang S (2013)     | 0.92 (0.32, 2.67) | 5.15 |
| Tang S (2013)     | 0.97 (0.35, 2.68) | 5.33 |
| Lu Y (2014)       | 0.54 (0.21, 1.37) | 5.62 |
| Saxena R (2014)   | 0.10 (0.04, 0.24) | 5.63 |
| Saxena R (2014)   | 0.20 (0.08, 0.50) | 5.63 |
| Saxena R (2014)   | 0.04 (0.01, 0.11) | 5.11 |
| Zhang G (2015)    | 0.84 (0.49, 1.41) | 7.24 |
| Zhang G (2015)    | 0.98 (0.49, 1.96) | 6.58 |
| Zhang G (2015)    | 1.24 (0.65, 2.38) | 6.77 |
| El-Maadawy EA (2019) | 0.34 (0.17, 0.68) | 6.56 |
| Riazzalhosseini B (2018) | 0.70 (0.31, 1.55) | 6.17 |
| Riazzalhosseini B (2018) | 0.72 (0.44, 1.18) | 7.38 |
| Overall (I-squared = 80.3%, p = 0.000) | 0.58 (0.39, 0.85) | 100.00 |

NOTE: Weights are from random effects analysis.
rs1800795 had significantly increased risks for developing liver diseases in all ethnic populations, especially HBV, HCV, HCC, NASH and alcoholic liver disease subgroups. On the contrary, G allele, GG or GC genotypes of rs1800796 may be significant protective factors for the development of liver diseases, especially HBV and Asian population. Although the overall and ethnic meta-analysis showed people carrying the GG, GA or GG+GA genotypes of rs1800797 had a higher risk of suffering liver diseases in non-Asian population, subgroup analysis seemed to show no significant association between this polymorphism and various subtypes of liver diseases except HCV identified in one article. For IL-6 rs2069837 and rs2066992 polymorphisms, we did not find any association with liver disease risk, although this was the first meta-analysis study to investigate them in liver diseases.

The differences in these 4 aspects may contribute to the slight deviation of our results from them. For example, the significant associations between IL-6 rs1800795 polymorphism and risk of HCC under homozygote model (CC vs GG: OR = 0.36; 95% CI = 0.16–0.85) and recessive model (GG+CG vs CC: OR = 2.82; 95% CI = 1.26–6.28) identified by Liu et al. were not observed in our study, but only significant under heterozygote model (GC vs CC: OR = 3.11, 95% CI = 1.24–7.79); significant associations between IL-6 rs1800797 polymorphism and the risk of HBV under allelic (G vs A: OR = 1.89; 95% CI = 1.11–3.20), heterozygote (GG vs GA: OR = 2.21; 95% CI = 1.12–3.92) and recessive (GA + AA vs GG: OR = 0.47; 95% CI = 0.26–0.86) models identified by Chang et al. were not shown in our study, but we found some novel conclusions, including significant associations with HBV, HCV, NASH, and alcoholic liver disease of rs1800795.

rs1800795 polymorphism is located at the 174 base pair upstream of IL-6 gene promoter and variation from G to C at this region was reported to reduce this gene’s transcription rate and lead to the lower production of IL-6. A recent study even found IL-6 mRNA expression was especially higher in the GC than in the GG and CC cases. It had been demonstrated hepatitis B core antigen transfection increased the expression and secretion of IL-6 through activating extracellular signal-related kinase, p38 mitogen-activated protein kinase and nuclear factor-kappa B in hepatocytes. Subsequently, HBV-IL-6 activated the transcription and translation of angiogenin and vascular endothelial growth factor genes via the STAT3 pathway and

Figure 4. Forest plots of the association of IL-6 gene rs1800797 polymorphism with an increased risk of liver diseases under homozygote (GG vs AA), heterozygote (GA vs AA) and dominant (GG+GA vs AA) models. A, homozygote; B, heterozygote; C, dominant. CI = confidence intervals; OR = odds ratio.
ultimately promoted HCC cell proliferation.\cite{10,47} Furthermore, activation of IL6/STAT3 pathway also could support HBV replication to further deteriorate HBV-related carcinogenesis.\cite{48} HCV infection was also proved to play important roles in the development of liver diseases by IL-6/STAT3 pathway.\cite{49} IL-6
level, which activated downstream immune and oxidative stress signaling to exacerbate inflammation infiltration, was also found to be increased in patients with NASH\cite{10} and alcoholic liver injury.\cite{11} Accordingly, we believe patients carrying GC genotype of rs1800795 may have higher risks to suffer HBV, HCV infection, HCC, NASH and alcoholic liver disease, which was in line with some studies showing the mRNA expressions of IL-6 was higher in the rs1800796 GG genotype compared with others.\cite{12,13}

rs1800796 polymorphism (-572 G/C) is also located within the promoter region of IL-6 gene. The individuals harboring -572GG or GC genotype was observed to have significantly lower IL-6 levels than those harboring the -572CC genotype.\cite{14} Also, CD14 (+) monocytes from subjects carrying the rs1800796C allele were shown to produce more IL-6 in response to in vitro HBV core antigen stimulation than those carrying G allele.\cite{15} Thus, rs1800796C allelic or genotype (CC or GC) polymorphism may be associated with an increased risk to HBV infection, which was confirmed in both of our study involving 1772 cases and 777 controls. However, this conclusion seemed to be only suitable to the Asian population. In the non-Asian group, GC and GG+GC genotype were risk factors for the development of liver diseases, which was in line with some studies showing the mRNA expressions of IL-6 was higher in the rs1800796 GG genotype compared with others.\cite{14,15}

### Table 6

| Comparison | Qualified studies | Test of association | Test of heterogeneity |
|------------|------------------|---------------------|----------------------|
| rs1800795 (G > C) | | | |
| Non-Asian | | | |
| Allelic (G vs C) | 17 | 1.12 (0.90–1.39) | .320 | R | .000 | 72.4 |
| Homozygote (GG vs CC) | 1.23 (0.84–1.78) | .288 | R | .005 | 55.1 |
| Heterozygote (GG vs GC) | 0.86 (0.63–1.19) | .369 | R | .000 | 73.3 |
| Heterozygote (GC vs CC) | 1.56 (1.27–1.93) | .000 | F | .365 | 8.0 |
| Dominant (GG+GC vs CC) | 1.42 (1.09–1.85) | .010 | F | .131 | 29.9 |
| Recessive (GG vs GC+CC) | 1.05 (0.77–1.43) | .764 | R | .000 | 77.0 |
| Asian | | | |
| Allelic (G vs C) | 3 | 1.59 (1.03–2.05) | .000 | F | .112 | 54.4 |
| Homozygote (GG vs CC) | 2.07 (1.03–4.59) | .075 | R | .027 | 72.4 |
| Heterozygote (GG vs GC) | 1.57 (1.23–1.99) | .000 | F | .877 | 0.0 |
| Heterozygote (GC vs CC) | 1.60 (1.15–2.22) | .005 | F | .018 | 75.2 |
| Dominant (GG+GC vs CC) | 1.55 (0.68–3.53) | .301 | R | .012 | 77.5 |
| Recessive (GG vs GC+CC) | 1.80 (1.44–2.26) | .000 | F | .591 | 0.0 |
| rs1800796 (G > C) | | | |
| Non-Asian | | | |
| Allelic (G vs C) | 4 | 1.02 (0.70–1.47) | .937 | R | .033 | 65.6 |
| Homozygote (GG vs CC) | 1.59 (0.78–3.26) | .204 | F | .343 | 10.1 |
| Heterozygote (GG vs GC) | 0.82 (0.49–1.40) | .473 | R | .016 | 71.1 |
| Heterozygote (GC vs CC) | 1.76 (1.11–2.79) | .017 | F | .692 | 0.0 |
| Dominant (GG+GC vs CC) | 1.85 (1.20–2.88) | .006 | F | .646 | 0.0 |
| Recessive (GG vs GC+CC) | 0.86 (0.49–1.50) | .587 | R | .007 | 75.4 |
| Asian | | | |
| Allelic (G vs C) | 12 | 0.87 (0.77–0.99) | .037 | R | .022 | 50.8 |
| Homozygote (GG vs CC) | 0.77 (0.59–1.00) | .046 | F | .140 | 31.4 |
| Heterozygote (GG vs GC) | 0.51 (0.30–0.85) | .009 | R | .000 | 81.0 |
| Heterozygote (GC vs CC) | 1.35 (0.97–1.89) | .077 | R | .000 | 86.9 |
| Dominant (GG+GC vs CC) | 1.02 (0.82–1.27) | .837 | R | .000 | 73.2 |
| Recessive (GG vs GC+CC) | 0.62 (0.45–0.85) | .003 | R | .007 | 57.3 |
| rs1800797 (G > A) | | | |
| Non-Asian | | | |
| Allelic (G vs A) | 4 | 1.00 (0.69–1.44) | .991 | R | .001 | 80.9 |
| Homozygote (GG vs AA) | 1.75 (1.21–2.53) | .003 | F | .080 | 55.6 |
| Heterozygote (GG vs GA) | 0.71 (0.37–1.36) | .300 | R | .000 | 82.3 |
| Heterozygote (GA vs AA) | 1.72 (1.19–2.49) | .004 | F | .536 | 0.0 |
| Dominant (GG+GA vs AA) | 1.76 (1.24–2.51) | .002 | F | .595 | 0.0 |
| Recessive (GG vs GA+AA) | 0.80 (0.43–1.51) | .406 | R | .000 | 83.6 |
| Asian | | | |
| Allelic (G vs A) | 4 | 1.30 (0.78–2.18) | .318 | R | .067 | 58.1 |
| Homozygote (GG vs AA) | 1.19 (0.55–2.56) | .658 | F | .337 | 8.0 |
| Heterozygote (GG vs GA) | 1.46 (0.83–2.55) | .191 | F | .133 | 46.4 |
| Heterozygote (GA vs AA) | 0.87 (0.39–1.93) | .726 | F | .554 | 0.0 |
| Dominant (GG+GA vs AA) | 1.07 (0.50–2.28) | .868 | R | .000 | 0.0 |
| Recessive (GG vs GA+AA) | 1.44 (0.80–2.60) | .230 | F | .085 | 54.7 |

CI = confidence interval, F = fixed-effects model. OR = odds ratios, R = random-effects model.
rs1800797 (-579 G/A) is also another polymorphism located within the promoter region of IL-6 gene. Our overall, non-Asian subgroup analysis and the study of Chang et al. [42] showed GG and GA genotype may be risk factors for liver diseases, indicating patients with these genotypes may have higher IL-6 levels. However, recent studies on lung cancer or obesity revealed IL-6 expression level was increased in an A allelic dose-dependent manner (that is, the highest for AA) [54,55], which may be attributed to the dual-function of IL-6 [56] or disease difference.

There are several limitations in this meta-analysis. First, the number of studies in some liver disease subtypes was relatively small and thus statistical power may be still sufficient to estimate the correlation between the IL-6 gene polymorphisms with them. Second, articles in languages other than English were not included in this meta-analysis. Third, although the meta-analysis only included case-control designed studies, several studies did not report whether they were age and sex matched, which may influence the credibility of conclusions. Fourth, although there were studies to indicate a linkage disequilibrium between some SNPs of IL-6 (such as rs1800796-rs1800797 [13], rs1800796-rs2066992 [14], rs2069837-rs17147230 [20], rs2069837-rs1524107-rs2066992 [19], rs17147230-rs2066992-rs2069837-rs2069852 [18], rs1800796-rs1800797 [13], and rs1800795-rs1800797 [17]), and haplotypes were calculated for more effective markers for prediction the risk of liver diseases, no meta-analysis was conducted for these haplotypes.
were reported. Fifth, the association between IL-6 level and IL-6 gene polymorphisms could not be evaluated to reveal the function mechanisms due to the lack of the related data.

In conclusion, our meta-analysis of 25 studies revealed that IL-6 rs1800795 (all ethnic populations) and rs1800797 (non-Asian) polymorphisms may be associated with an increased risk of liver diseases, while rs1800796 polymorphism was associated with a decreased susceptibility factor for liver diseases in Asian population. The absence of a relationship between IL-6 rs2069837 and rs2066992 polymorphisms and the risk of liver diseases was demonstrated. A similar conclusion was found in the HBV, HCV, HCC, NASH and alcoholic liver disease population for rs1800795; HBV subgroup for rs1800796; and HCV subgroup for rs1800797.

**Author contributions**

Conceptualization: Xuehan Wang.

Data curation: Xuehan Wang, Zhenghui Yan.

Formal analysis: Xuehan Wang, Zhenghui Yan, Qingjian Ye.

Investigation: Zhenghui Yan.

Methodology: Zhenghui Yan.

Writing – original draft: Xuehan Wang, Qingjian Ye.

Writing – review & editing: Xuehan Wang, Qingjian Ye.

**References**

[1] Vikramjit M, Jane M. Metabolic functions of the liver. An aesth Intensive Care Med 2009;10:334–5.

[2] Knolle PA, Wollheider D. Immunological functions of liver sinusoidal endothelial cells. Cell Mol Immunol 2016;13:347–53.

[3] Grant DM. Detoxification pathways in the liver. J Inherit Metab Dis 1991;14:421–30.

[4] Chen W, Zheng R, Basde PD, et al. Cancer statistics in China, 2015. Ca Cancer J Clin 2016;66:115–32.

[5] Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol 2017;66:1300–12.

[6] Gudowska-Sawczuk M, Wrona A, Gruszewska E, et al. Serum level of interleukin-6 (IL-6) and N-terminal propeptide of procollagen type I (PINP) in patients with liver diseases. Scand J Clin Lab Invest 2018;78:125–30.

[7] Kim HY, Jho JJ, Cho ML, et al. Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B failure. J Gastroenterol Hepatol 2014;49:1264–73.

[8] Fuster D, Tsui JI, Cheng DM, et al. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. AIDS Res Hum Retroviruses 2013;29:1110–6.

[9] Shao YY, Lin H, Li YS, et al. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. Jpn J Clin Oncol 2017;47:949–53.

[10] Hu Z, Luo D, Wang D, et al. IL-17 activates the IL-6/STAT3 signal pathway in the proliferation of hepatitis B virus-related hepatocellular carcinoma. Cell Physiol Biochem 2017;43:2379–90.

[11] Wang Z, Wu S, Liao J, et al. Interleukin-6 and rs1800796 locus single nucleotide polymorphisms in response to hypoxia/reoxygenation in hepatocytes. Int J Mol Med 2013;38:192–200.

[12] Zhang G, Wang W, Li S, et al. IL6 gene allele-specific C/EBP(-binding activity affects the development of HBV infection through modulation of Th17/Treg balance. Genes Immun 2015;16:528–35.

[13] El-Maadawy EA, Talaat RM, Ahmed MM, et al. Interleukin-6 promoter gene polymorphisms and susceptibility to chronic hepatitis B virus in Egyptians. Hum Immunol 2019;80:208–14.

[14] Razalihosseini B, Mohamed Z, Apalasamy YD, et al. Interleukin-6 gene variants are associated with reduced risk of chronicity in hepatitis B virus infection in a Malaysian population. Biomed Rep 2018;9:313–20.

[15] Tang S, Liu Z, Zhang Y, et al. Rather than Rs1800796 polymorphism, expression of interleukin-6 is associated with disease progression of chronic HBV infection in a Chinese Han population. Dis Markers 2013;35:799–805.

[16] Cussigh A, Falleti E, Frabisi C, et al. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics 2015:65:33–41.

[17] Falleti E, Frabisi C, Toniutto P, et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 2015;77:304–13.

[18] Zhao XM, Gao YF, Zhou Q, et al. Relationship between interleukin-6 polymorphism and susceptibility to chronic hepatitis B virus infection. World J Gastroenterol 2013;19:6888–93.

---

**Figure 6.** Sensitivity analysis for the assessment of result stability for rs1800795 polymorphism (GC vs CC). CI = confidence intervals.
[19] Wang J, Chen R, Tang S, et al. Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in antituberculosis drug-induced hepatitis in a nested case-control study. PLoS One 2015;10:e0118862.

[20] Zheng X, Han C, Shan R, et al. Association of interleukin-6 polymorphisms with susceptibility to hepatocellular carcinoma. Int J Clin Exp Med 2015;8:6232–6.

[21] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647–17647.

[22] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[23] Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:453–63.

[24] Yousefi N, Najafi M, Motamed F, et al. Association of Interleukin-6 and Interleukin-1 Family Gene Polymorphisms in Autoimmune Hepatitis. Ann Hepatol 2018;17:1021–5.

[25] Carulli L, Canedi I, Rondinella S, et al. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis 2009;41:823–8.

[26] Bocsan IC, Milaciu MV, Pop RM, et al. Cytokines genotype-phenotype correlation in nonalcoholic steatohepatitis. Oxid Med Cell Longev 2017;2017:4297206.

[27] Motawi T, Shaker OG, Hussein RM, et al. Polymorphisms of (1-antitrypsin and Interleukin-6 genes and the progression of hepatic carci...